Trilobine and its natural analogs for use as a drug
US10517863B2 · kind B2 · utility
0Cited by
0References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 3, 2016 |
| Grant date | Dec 31, 2019 |
| Priority date | — |
| Expiry date | Oct 3, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2300/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues as DNMT inhibitors for use as a drug for the treatment of cancer and neurological diseases and for cell reprogramming, in particular to prime for chemotherapy or immunotherapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.